Anti-MMP-7 Rabbit Polyclonal Antibody
- Host
- Rabbit, Polyclonal
- Reactivity
- Validated- Human Potential-Mouse, Rat, Pan, Monkey, Dog, Cat, Pig
- UniProt
- P09237
- Size
- 100ug
- Cat. #
- RP1MMP7
In stock
- SKU
- RP-MMP7
Target Overview
Matrix metalloproteinase-7 (MMP-7, EC 3.4.24.23), also known as matrilysin or Pump-1 protease, is a secreted zinc-dependent endopeptidase that degrades extracellular matrix components including casein, gelatins (types I, III, IV, and V), and fibronectin. Unlike most MMPs, MMP-7 lacks a hemopexin domain and functions as a minimal MMP consisting of only prodomain and catalytic domain. It is localized to the extracellular space and matrix, where it plays roles in tissue remodeling, inflammation, and cellular invasion. MMP-7 activates procollagenase and processes latent forms of other matrix-degrading enzymes, functioning as an upstream regulator in proteolytic cascades. Originally identified in uterine tissue, MMP-7 is now recognized for broader expression in epithelial cells of multiple organs. Researchers study MMP-7 in contexts ranging from wound healing and inflammatory bowel disease to tumor invasion and metastasis, where its matrix-degrading activity facilitates cell migration and tissue remodeling. The 267-amino acid protein (UniProt P09237) is synthesized as a proenzyme requiring activation through cleavage of the prodomain.
Background
MMP-7 belongs to the matrix metalloproteinase family of zinc-dependent endopeptidases responsible for extracellular matrix turnover and remodeling. Its broad substrate specificity includes collagens, laminins, entactin, and proteoglycans, allowing it to remodel basement membranes and stromal matrices. Beyond structural substrates, MMP-7 processes bioactive molecules including E-cadherin, Fas ligand, and pro-defensins, implicating it in epithelial integrity, immune regulation, and antimicrobial defense. The enzyme is synthesized as an inactive zymogen and activated in the extracellular space through proteolytic removal of the prodomain.
Aberrant MMP-7 expression has been documented across multiple pathologies. Elevated MMP-7 correlates with fibrotic progression in liver, lung, and kidney disease, where matrix remodeling contributes to tissue scarring. Yang et al. (2026) identified MMP-7 as a candidate non-invasive fibrosis marker in biliary atresia, reflecting its utility in monitoring matrix remodeling in pediatric hepatobiliary disease. In oncology, MMP-7 overexpression associates with invasive phenotypes and poor prognosis in colorectal, gastric, and breast cancers. Recent integrated analyses have examined MMP-7 transcript signatures as predictive biomarkers in breast cancer survival models, emphasizing its role in tumor microenvironment remodeling.
MMP-7 also participates in inflammatory processes, where its expression is induced by cytokines and microbial products. Studies have linked MMP-7 to preterm labor inflammatory cascades and intervertebral disc degeneration stress responses, underscoring its involvement in tissue injury and repair. Triple Point Biologics offers four rabbit polyclonal antibodies targeting the aminoterminal region of the active enzyme, validated for Western blot applications in human samples with predicted cross-reactivity in mouse, rat, and other mammalian species.
References
- Yang Y et al (2026) Comparison of non-invasive liver fibrosis indicators for biliary atresia. Pediatr Surg Int. PubMed · 10.1007/s00383-026-06478-4
- Babas R et al (2026) Integrative Survival Prediction in Breast Cancer Using Extracellular Matrix Protease Transcript Signatures and Clinical Variables: A Machine Learning Approach. Cancers (Basel). PubMed · 10.3390/cancers18101497
- Hong S et al (2026) Vaginal dysbiosis and inflammatory signatures in preterm labor: an integrated model for predicting preterm birth. Front Immunol. PubMed · 10.3389/fimmu.2026.1809046
- Kanelis E et al (2026) Secretome and Pathway Analysis of Stress Induced Disc Degeneration In Vitro. JOR Spine. PubMed · 10.1002/jsp2.70165
- Misar PL et al (2026) Pharmacological repurposing of cilostazol to attenuate the progression of pulmonary fibrosis: efficacy validation via integrated network pharmacology and in vivo experimentation. Naunyn Schmiedebergs Arch Pharmacol. PubMed · 10.1007/s00210-026-05488-2
Additional Specifications
| Gene Symbol | MMP7 |
|---|---|
| UniProt ID | P09237 |
| Host Species | Rabbit |
| Species Reactivity | Validated- Human Potential-Mouse, Rat, Pan, Monkey, Dog, Cat, Pig |
| Pack Size | 100ug |
| Immunogen (Â Aminoterminal end of active enzyme) | Immunogen is proprietary and confidential. Immunogen generated in amino acid region 95-145. |
| Immunogen (aminoterminal end of catalytic zinc site) | Immunogen is proprietary and confidential. Immunogen generated in amino acid region 95-135. |
| Immunogen (Middle of active MMP-7) | Immunogen is proprietary and confidential. Immunogen generated in amino acid region 185-210. |
| Immunogen (Propeptide region) | Immunogen is proprietary and confidential. Immunogen generated in amino acid region 18-94. |
| Alternate Names | MMP-7, Matrilysin, Matrin, Matrix metalloproteinase-7, Pump-1 protease, Uterine metalloproteinase, EC 3.4.24.23 |
Frequently Asked Questions
What molecular weight band should I expect for MMP-7 on a Western blot?
MMP-7 migrates as a 28 kDa band corresponding to the mature, active enzyme after prodomain cleavage. You may also detect a 48 kDa proenzyme form, particularly in cell lysates where the zymogen has not yet been activated. The absence of a hemopexin domain makes MMP-7 significantly smaller than most other MMPs. Band intensity and the ratio of pro- versus mature forms depend on your sample type and activation state. Epithelial cell lines and tissue lysates from organs with high MMP-7 expression typically show both forms, while conditioned media from secreting cells may favor the mature species.
Does MMP-7 have splice isoforms I need to account for?
MMP-7 is encoded by a single exon structure with no well-characterized splice variants in humans. The primary transcript yields a single polypeptide of 267 amino acids, processed to the active 28 kDa form. This simplicity contrasts with some other MMPs that exhibit tissue-specific isoforms. When interpreting Western blots, band complexity usually reflects post-translational processing—proenzyme versus active form, or proteolytic fragments—rather than alternative splicing. This makes MMP-7 a relatively straightforward target for antibody detection, with predictable molecular weights and minimal isoform ambiguity across tissues.
What starting dilution should I use for Western blot with this MMP-7 antibody?
Start at 1:1000 dilution in blocking buffer for Western blot applications, as recommended in the product specification. This rabbit polyclonal has been validated at this dilution for human samples. Optimal dilution may vary with your sample type, target abundance, and detection system sensitivity. For tissues or cell lines with low MMP-7 expression, titrate between 1:500 and 1:1000. Conversely, if working with epithelial cells known to express high levels—such as colonic or mammary epithelium—1:2000 may suffice and reduce background. Always include a positive control lysate from MMP-7-expressing cells to confirm antibody performance.
Will this antibody detect mouse or rat MMP-7 in my samples?
This antibody has been validated for human MMP-7 detection; reactivity with mouse and rat is predicted but not experimentally confirmed by the manufacturer. Human and mouse MMP-7 share approximately 82 percent amino acid identity, and rat shows similar homology, suggesting cross-reactivity is likely. However, we recommend testing the antibody on positive control lysates from your species before committing to large-scale experiments. If working with rodent models, verify detection by running parallel samples from mouse or rat epithelial tissues known to express MMP-7, such as small intestine or uterus, alongside human controls.
What sample preparation method works best for detecting secreted MMP-7?
MMP-7 is a secreted protease localized to the extracellular space, so conditioned cell culture media and tissue homogenate supernatants are ideal sample types. For conditioned media, concentrate samples 10- to 20-fold using centrifugal filters (10 kDa cutoff) to enrich MMP-7 and improve detection sensitivity. Avoid prolonged incubation at room temperature, as MMP-7 can degrade itself and other proteins. For tissue samples, homogenize in neutral pH buffer with protease inhibitors, then clarify by centrifugation and collect the soluble fraction. Avoid strong detergents if you plan enzymatic activity assays alongside Western blotting.
Can I use this antibody for immunohistochemistry on paraffin sections?
Yes, Triple Point Biologics antibodies are validated for Western blot; IHC application data is in progress sections. For MMP-7, perform antigen retrieval using citrate buffer (pH 6.0) with heat-induced epitope unmasking to expose masked epitopes in fixed tissue. MMP-7 localizes to epithelial cells and the extracellular matrix, so expect cytoplasmic and pericellular staining patterns in positive tissues such as colon, breast, and pancreatic epithelia. Start with a 1:100 to 1:200 dilution and optimize based on signal intensity and background. Include appropriate positive control sections from tissues known to express MMP-7.
How should I store this MMP-7 antibody to maintain stability?
Store the antibody at -20°C in single-use aliquots to avoid repeated freeze-thaw cycles, which can compromise antibody integrity and reduce titer over time. Upon receipt, aliquot the 100 µg stock into working volumes appropriate for your typical experiment scale—10 to 20 µL aliquots work well for most labs. Thaw aliquots on ice, and once thawed, keep at 4°C for short-term use within one to two weeks. Do not refreeze thawed aliquots. For long-term storage beyond six months, verify antibody performance with a control blot before critical experiments.
What positive and negative controls should I run when validating this MMP-7 antibody?
Use lysates from epithelial cell lines known to express MMP-7, such as HT-29 colorectal or MCF-7 breast cancer cells, as positive controls. Negative controls should include cell types with minimal MMP-7 expression, such as fibroblasts or lymphocytes. For peptide competition controls, pre-incubate the antibody with recombinant MMP-7 protein or the immunizing peptide if available to confirm specificity. Knockout or siRNA-mediated knockdown lysates provide the most rigorous negative control. Running these controls in parallel with experimental samples allows you to distinguish specific MMP-7 signal from non-specific binding or cross-reactive bands.
Validation imagery coming soon
Western blot validation figures for RP-MMP7 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.
Also known as:
- MMP-7
- Matrilysin
- Matrin
- Matrix metalloproteinase-7
- Pump-1 protease
- Uterine metalloproteinase
- EC 3.4.24.23